沙库巴曲缬沙坦联合整合式管理在心力衰竭 合并肾功能不全治疗中的应用
作者:
作者单位:

作者简介:

刘涛,男,副主任医师,主要从事冠心病、心脏瓣膜病、高血压、难治性心力衰竭的诊治,冠状动脉 的介入治疗等方面工作。

通讯作者:

中图分类号:

R 541.6

基金项目:

江西省卫生健康委科技计划项目(202212583)


Application of Sacubitril Valsartan Combined with Integrated Management in Patients with Heart Failure and Renal Insufficiency
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    摘 要目的:探讨沙库巴曲缬沙坦联合整合式管理干预在心力衰竭合并肾功能不全患者临床治疗中的价值。 方法:选取瑞金市人民医院 2021 年 1 月至 2021 年 12 月收治的 100 例心力衰竭合并肾功能不全患者,随机分为对照组和观察组,各 50 例。对照组患者在常规管理基础上使用沙库巴曲缬沙坦进行治疗,观察组患者在对照组基础上联合整合式管理进行治疗。 比较两组患者心功能、临床症状改善情况、生活质量、临床指标。 结果:治疗后,两组患者心功能检测项均有改善,观察组 患者心率、左心室收缩末期内径均低于对照组,且观察组左心室射血分数高于对照组,差异均具有统计学意义(P < 0.05)。 观察组患者各项临床症状改善占比均高于对照组,差异具有统计学意义(P < 0.05)。治疗后,两组患者明尼苏达州心功 能不全生命质量量表(MLHFQ)评分均降低,且观察组低于对照组,差异具有统计学意义(P < 0.05)。治疗后,观察组 患者血肌酐清除率、肾小球滤过率均高于对照组,N 末端脑钠肽前体水平低于对照组,差异均具有统计学意义(P < 0.05)。 结论:沙库巴曲缬沙坦联合整合式管理干预,能够提高患者治疗配合度,同时进一步改善了患者的预后及生活质量。

    Abstract:

    AbstractObjective To explore the value of integrated management intervention combined with sacubitril valsartan in the clinical treatment of patients with heart failure and renal insufficiency. Methods 100 patients with heart failure and renal insufficiency admitted to People's Hospital of Ruijin City from January 2021 to December 2021 were randomly divided into a control group and an observation group, with 50 patients in each group. The control group patients were treated with sacubitril valsartan on the basis of routine management, while the observation group patients were treated with integrated management on the basis of the control group. The cardiac function, clinical symptom improvement, quality of life, and clinical indicators between the two groups of patients were compared. Results After treatment, the levels of cardiac function testing improved in both groups of patients. The heart rate and left ventricular end systolic diameter of the observation group were lower than those of the control group, and the left ventricular ejection fraction of the observation group was higher than that of the control group, the differences were statistically significant (P < 0.05). The proportion of patients with improved clinical symptoms in the observation group was higher than that in the control group, and the difference was statistically significant (P < 0.05). After treatment, the Minnesota living with heart failure questionnaire (MLHFQ) scores of both groups of patients decreased, and the score of the observation group was lower than that in the control group, with statistical significance (P < 0.05). After treatment, the blood creatinine clearance rate and glomerular filtration rate in the observation group were higher than those in the control group, and the level of N-terminal pro-brain natriuretic peptide in the observation group was lower than that in the control group, the differences were statistically significant (P < 0.05). Conclusion The combination of sacubitril valsartan and integrated management intervention can improve the patient's treatment compatibility, while further improving the patient's prognosis and quality of life.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-06-10
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-11-03
  • 出版日期:
重要通知

近期有不法分子冒充我刊名义给作者打电话或发邮件,提示关于“知网、万方、维普等数据调整通知”或其他莫名原由,要求添加微信。我刊在此声名:杂志社与作者沟通方式为电话与邮件(在杂志社网站的“联系我们”下拉菜单,或者网站最下端信息栏可以查到),不会要求作者添加微信。另,此网站为本刊唯一官方网站,其他均为假冒网站。望广大作者提高警惕,谨防上当。谢谢配合! 《深圳中西医结合杂志》编辑部

关闭